SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (310)9/18/2002 9:21:40 AM
From: quidditch  Read Replies (1) of 508
 
The trial's Data Safety and Monitoring Board stopped the study after six months due to an imbalance in life threatening acute exacerbations in favor of pirfenidone. At the time the study was ended, there was a trend for efficacy in the primary endpoint in the overall population of pirfenidone treated patients and a significant effect on the primary endpoint in a pre-specified group of those patients who could complete the standard six-minute walk test at baseline. There were also trends for efficacy in favor of pirfenidone in the secondary endpoints.

In the occluded language of medical researchers, I infer, in the context of the rest of the paragraph, that the study was discontinued because results clearly showed that the drug was helping and that it would be unethical to continue the trial.

Is that right?

quid
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News